Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, University Hospital, Singapore.
BJOG. 2010 Sep;117(10):1270-7. doi: 10.1111/j.1471-0528.2010.02602.x.
We studied the efficacy of 25-microg misoprostol pessaries as either single or double dose compared with a 3-mg dinoprostone pessary for cervical priming.
A randomised controlled trial in Singapore.
One hundred and seventy-one women with term pregnancies and modified Bishop scores (mBS) < or =6 from 2003 to 2004.
Patients were randomised to single misoprostol dose, double misoprostol dose or the current dinoprostone regimen.
Primary outcome was number of women who achieved favourable mBS >6 or active labour by day 2. Secondary outcomes were time interval from insertion to delivery, cardiotocographic abnormalities, delivery and neonatal outcome.
More women in the misoprostol double-dose group (96.6%) and dinoprostone group (93%) achieved the primary outcome compared with the single-dose group (77.8%) (P = 0.003 and P = 0.03, respectively). There was no difference in secondary outcomes. More multiparous women achieve primary outcome compared with nulliparous women (odds ratio 0.21, 95% confidence interval 0.06-0.77).
Double-dose misoprostol 25 microg is as effective as dinoprostone 3 mg inserts for cervical priming; both are more efficacious than a single-dose misoprostol pessary. Parity prognosticates the success of induction.
我们研究了与 3mg 地诺前列酮栓相比,25μg米索前列醇阴道栓剂单次或双次给药用于宫颈预处理的效果。
在新加坡进行的一项随机对照试验。
2003 年至 2004 年期间,171 名足月妊娠且改良 Bishop 评分(mBS)≤6 的妇女。
患者被随机分为米索前列醇单次剂量组、米索前列醇双次剂量组或现行地诺前列酮方案组。
主要结局为 mBS>6 或第 2 天进入活跃期的妇女人数。次要结局为从放置到分娩的时间间隔、胎心监护异常、分娩和新生儿结局。
米索前列醇双次剂量组(96.6%)和地诺前列酮组(93%)的妇女比米索前列醇单次剂量组(77.8%)更能达到主要结局(P=0.003 和 P=0.03)。次要结局无差异。与初产妇相比,多产妇更能达到主要结局(优势比 0.21,95%置信区间 0.06-0.77)。
双次剂量 25μg米索前列醇与 3mg 地诺前列酮栓用于宫颈预处理同样有效;两者均优于单次剂量米索前列醇栓。产次预测了引产的成功率。